A crossover investor in the life sciences

Nexus Life Science Partners has been investing in private and public life sciences companies since 2001, with a proven track record of performance.

Nexus Life Science Partners is an investment management company focused on crossover private equity investing in the life sciences industry.

Nexus Life Science Partners invests globally in private and public healthcare companies and manages several crossover private equity funds with capital commitments totaling $200 million. Our investor base consists of financial institutions, funds of funds, family offices and high net worth individuals.


Robertson Stephens - Head, Healthcare Private Capital Markets (1998-2001)
New York Life - Portfolio Manager, Healthcare Private Equity (1993-1998)
Citibank - Biotechnology Research Analyst, Asset Management (1989-1992)
Biogen - Head, Sequencing Lab (1983-1987)

New York University, MS, Economics (1995)
University of Neuchâtel (Switzerland), Licence ès Science, Molecular Biology (1982)


Merlin BioMed Group (2004-2006)
Anchin, Block & Anchin , LLP - Audit & Tax Supervisor, Financial Services (1999-2004)

Binghamton University, BS, Accounting (1999)

Performance Redefined

Nexus Life Science Partners believes the pre- and post-IPO segment is a source of superior life sciences investment opportunities. This investment "space" generates two distinct sets of opportunities: private investments in late-stage private companies and private investments in public companies (PIPES).

Our crossover strategy enables us to take advantage of valuation disparities between the private and public markets. Unlike venture capital funds, Nexus Life Science Partners funds are characterized by relatively high liquidity and short fund term. Our strategy minimizes binary risk and results in balanced returns.

Contact Us

Contact Us

Thank You Your information has been submitted successfully

Contact Us

We Apologize You're request was not processed correctly. Please try your submission again.